AI In Pharma Market Expansion Continues, with Forecast Valuation of $9.64 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

AI In Pharma Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of AI in the pharmaceutical sector has been expanding tremendously in the past few years. The growth is projected to rise from $2.92 billion in 2024 to $3.8 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 30.1%. The historic growth has been a result of amplified utilization of artificial intelligence for affordable drug discovery and increased adoption of AI in the radiology field.

AI In Pharma Market Size Forecast: What's the Projected Valuation by 2029?
The market size of AI in the pharmaceutical industry is predicted to experience significant expansion in the upcoming years. Expected to swell to a value of $9.64 billion by 2029, the market will have a compound annual growth rate (CAGR) of 26.2%. The projected growth can be assigned to various factors, including the increasing reliance on cloud-based applications and services, rising healthcare costs, and expanding government initiatives to boost AI development. Key trends to observe during the forecast period are the rise of generative AI in the pharmaceutical sector, application of AI for molecular target detection, incorporation of AI in drug screening workflows, improvements in AI tools for pharmaceuticals, growing inflow of funds in developing new AI solutions, and increased strategic partnerships within the market players.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ai-in-pharma-global-market-report

What Are the Drivers Transforming the AI In Pharma Market?
The anticipated growth of the AI in pharma market is largely attributed to the escalating government backing for AI development. The transformative impact of AI technologies in the pharmaceutical industry has been acknowledged by governments, who are subsequently enforcing policies and initiatives to encourage their uptake. Several nations have formulated national AI strategies that incorporate emphasis on healthcare and pharmaceutical facets. The motive behind these schemes is to propel the development and allocation of AI technology to endorse scientific growth and address existing challenges in the country. As a significant instance in April 2022, the Australian government declared a financier scheme valued at AUD 44 million ($29.61 million) to encourage AI research among small and medium-scale enterprises (SMEs). This step is intrinsic to a broader strategy striving to elevate the use of AI in Australia's prime national manufacturing sectors and leading digital growth areas, encompassing the pharma industry. The fund allocation will establish digital proficiency centers, considered hubs for AI research and development. These centers will impart necessary resources, training, and support to SMEs, facilitating them to innovate and apply AI technologies. Consequently, the burgeoning government backing will fuel the growth dynamics of the AI in pharma market throughout the prediction period.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3887&type=smp

What Long-Term Trends Will Define the Future of the AI In Pharma Market?
A significant trend in the AI for pharma market is the introduction of new AI technologies by operating companies that will prove advantageous for pharmaceutical corporations. AI's benefits span across quality control, predictive servicing, waste diminution, design enhancement, and process automation. For example, in August 2022, both Sanford Health and Sharp HealthCare, US-based non-profit healthcare organizations, collaborated with Dandelion Health, an American healthcare AI company. They devised a comprehensive data platform that provides healthcare institutions with access to superior, representative patient data for clinical AI development. Constructed to offer health AI developers secure and ethical access to patient datasets, including images, waveforms, and structured health records, the Dandelion Platform facilitates the creation of tools and products aimed to assist patients and medical practitioners.

Which Segments in the AI In Pharma Market Offer the Most Profit Potential?
The AI in pharma market covered in this report is segmented -

1) By Technology: Context-Aware Processing, Natural Language Processing, Querying Method, Deep Learning
2) By Drug Type: Small Molecule, Large Molecules
3) By Application: Diagnosis, Clinical Trial Research, Drug Discovery, Research and Development, Epidemic Prediction

Subsegments:
1) By Context-Aware Processing: Real-Time Data Processing, Contextual Recommendation Systems, Adaptive Learning Systems
2) By Natural Language Processing (NLP): Text Analytics And Sentiment Analysis, Chatbots And Virtual Assistants, Document And Data Mining
3) By Querying Method: Structured Querying, Unstructured Querying, Semantic Search Technologies
4) By Deep Learning: Neural Networks For Drug Discovery, Image Recognition For Medical Imaging, Predictive Analytics Models

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3887&type=smp

Which Firms Dominate the AI In Pharma Market by Market Share and Revenue in 2025?
Major companies operating in the AI in pharma market include Concerto HealthAI, Alphabet Inc., OWKIN, Nvidia Corporation, PathAI, Insilico Medicine, Exscientia, Microsoft Corporation, XtalPi, Intel, Standigm, Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Jiangsu Hengrui Medicine Co. Ltd, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Sun Pharma, Alliance Pharm Pte Ltd., Shanghai Pharmaceuticals, DeepMind, GlaxoSmithKline, Sanofi, Bayer, Renalytix AI, Merck, AstraZeneca, Iktos, Benevolent AI, Novartis, Ardigen, Botkin, Webiomed, Care Mentor AI, Diagnocat, IBM Corporation, Atomwise Inc., Cloud Pharmaceuticals, Bioage, NuMedii, Envisagenics, Aria Pharmaceuticals, Verge Genomics, Berg LLC, Cyclica, IQVIA, Roche, Pfizer, PRA Health Science, Gesto, Intensicare, Epitrack, Deep Genomics Inc., Welltok Inc., Oncora Medical, Recursion Pharmaceuticals Inc., Nucleai, Pepticom, Rology, hearX Group, DilenyTech, iNNOHEALTH Technology Solutions

Which Regions Offer the Highest Growth Potential in the AI In Pharma Market?
North America was the largest region in the AI in pharma market in 2024. The regions covered in the AI in pharma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3887

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.